Ruth E. Langley - Concepedia

Author

Ruth E. Langley

Also Known As

Langley, Ruth E, Mahesh Parmar, R E Langley, R Langley, R. E. Langley, R. Langley, R.E. Langley, Ruth E Langley, Ruth E. Langley, Ruth Elizabeth Langley

193

Publications

15.8K

Citations

H-Index

Concepts

All Affiliations

University College London MRC Clinical Trials Unit at UCL Medical Research Council Royal Marsden NHS Foundation Trust Royal Marsden Hospital

About

Ruth E. Langley is an author at University College London specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.6K
2	Health Sciences	7	7	784
3	Public Health	2	2	36
4	Education	1	1	10
5	Biostatistics	1	1	21

Ruth E. Langley

Publications

14.1K

Citations

H-Index

Page 1

	Year	Citations
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer David Cunningham, William Allum, Sally Stenning, New England Journal of Medicine	2006	6.3K
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Christopher Parker, Nicholas D. James, Chris Brawley, The Lancet	2018	1.2K
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer William Allum, Sally Stenning, J Bancewicz, Journal of Clinical Oncology	2009	982
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial P. Mulvenna, Matthew Nankivell, Rachael Barton, The Lancet	2016	710
Mismatch Repair Deficiency, Microsatellite Instability, and Survival Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt, JAMA Oncology	2017	509
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial Lindsay C Thompson, Harpreet Wasan, Gary Middleton, The Lancet Geriatric OncologyOncologyGeriatricsCancer ManagementClinical Trials	2011	412
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial N.W. Clarke, Amin Ali, Fiona C. Ingleby, Annals of Oncology	2019	389
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial Elizabeth Smyth, Matteo Fassan, David Cunningham, Journal of Clinical Oncology	2016	298
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial David Cunningham, Sally Stenning, Elizabeth Smyth, The Lancet Oncology	2017	282
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial Derek Alderson, David Cunningham, Matthew Nankivell, The Lancet Oncology	2017	219

Page 1